Last reviewed · How we verify
NCT06671808
HIV and Multi-Drug Resistant Tuberculosis: a Study on Clinical Outcomes
trial testing Examination of HIV Infection in Patients with Multi-Drug Resistant Tuberculosis (MDR-TB) in HIV Infection in 222,128 participants. Completed in 3 September 2024.
22 August 2024
Quick facts
| Lead sponsor | Zahedan University of Medical Sciences |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 222,128 |
| Start date | 15 May 2024 |
| Primary completion | 22 August 2024 |
| Estimated completion | 3 September 2024 |
| Sites | 1 location across Iran |
Drugs / interventions tested
- Examination of HIV Infection in Patients with Multi-Drug Resistant Tuberculosis (MDR-TB)
Conditions studied
- HIV Infection — all drugs for HIV Infection →
- MDR-TB — all drugs for MDR-TB →
Sponsor
Zahedan University of Medical Sciences
Who can join
18 and older, any sex, with HIV Infection or MDR-TB. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to investigate the relationship between HIV infection and multi-drug resistant tuberculosis (MDR-TB) among affected individuals in Zahedan, Iran. It will involve a detailed analysis of patient demographics, clinical characteristics, and treatment outcomes to enhance understanding of this co-infection. The findings may inform better treatment strategies and healthcare policies for managing these diseases in similar populations.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06671808
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HIV Infection
Currently open trials in the same condition.
- NCT06900829 — #AWARE.HIV Europe: Supporting Healthcare Professionals to Find Undiagnosed HIV in European Hospitals: An Effectiveness-i · NA · recruiting
- NCT06908252 — MAPS PrEP Van Study · Phase 4 · recruiting
- NCT07042945 — MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003) · Phase 1 · recruiting
- NCT06716450 — Multiplo Tp/HIV Self-Test · NA · recruiting
- NCT07086989 — Cardiovascular Risk in Children With Chronic Conditions Study · recruiting
Other Zahedan University of Medical Sciences trials
Trials by the same sponsor.
- NCT07343011 — Conjunctival Transpositional Surgery for Primary Pterygium · NA · recruiting
- NCT07430020 — Shared Decision-Making Counseling and Breastfeeding Performance Among Primiparous Women in Iran · NA · completed
- NCT07022860 — Study on Platelet-Rich Fibrin for Preserving Jawbone After Tooth Extraction Using CBCT Imaging in Adults · NA · completed
- NCT06677281 — Impact of COVID-19 on Pregnancy Outcomes: a Systematic Review · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06671808 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zahedan University of Medical Sciences
- Last refreshed: 4 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06671808.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing